93 related articles for article (PubMed ID: 28291248)
1. A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.
Zhong Q; Guo T; Rechsteiner M; Rüschoff JH; Rupp N; Fankhauser C; Saba K; Mortezavi A; Poyet C; Hermanns T; Zhu Y; Moch H; Aebersold R; Wild PJ
Sci Data; 2017 Mar; 4():170014. PubMed ID: 28291248
[TBL] [Abstract][Full Text] [Related]
2. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
3. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
Yoshimoto M; Cutz JC; Nuin PA; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA
Cancer Genet Cytogenet; 2006 Sep; 169(2):128-37. PubMed ID: 16938570
[TBL] [Abstract][Full Text] [Related]
4. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
5. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
6. Automated multiplexing quantum dots in situ hybridization assay for simultaneous detection of ERG and PTEN gene status in prostate cancer.
Zhang W; Hubbard A; Brunhoeber P; Wang Y; Tang L
J Mol Diagn; 2013 Nov; 15(6):754-64. PubMed ID: 23994645
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
8. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.
Zhong Q; Rüschoff JH; Guo T; Gabrani M; Schüffler PJ; Rechsteiner M; Liu Y; Fuchs TJ; Rupp NJ; Fankhauser C; Buhmann JM; Perner S; Poyet C; Blattner M; Soldini D; Moch H; Rubin MA; Noske A; Rüschoff J; Haffner MC; Jochum W; Wild PJ
Sci Rep; 2016 Apr; 6():24146. PubMed ID: 27052161
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
10. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts.
Harmon SA; Patel PG; Sanford TH; Caven I; Iseman R; Vidotto T; Picanço C; Squire JA; Masoudi S; Mehralivand S; Choyke PL; Berman DM; Turkbey B; Jamaspishvili T
Mod Pathol; 2021 Feb; 34(2):478-489. PubMed ID: 32884130
[TBL] [Abstract][Full Text] [Related]
11. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
12. [Tissue microarray--an infrastructure for prostate cancer outcome research].
Zisman A; Rozin LS; Stav K; Merded H; Lindner A; Sandbank J
Harefuah; 2005 Sep; 144(9):622-5; 677. PubMed ID: 16218532
[TBL] [Abstract][Full Text] [Related]
13. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.
Ibeawuchi C; Schmidt H; Voss R; Titze U; Abbas M; Neumann J; Eltze E; Hoogland AM; Jenster G; Brandt B; Semjonow A
Int J Mol Sci; 2015 Feb; 16(2):3856-69. PubMed ID: 25679447
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study.
McCann SM; Jiang Y; Fan X; Wang J; Antic T; Prior F; VanderWeele D; Oto A
AJR Am J Roentgenol; 2016 Mar; 206(3):559-65. PubMed ID: 26901012
[TBL] [Abstract][Full Text] [Related]
15. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
[TBL] [Abstract][Full Text] [Related]
18. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion.
Verhagen PC; van Duijn PW; Hermans KG; Looijenga LH; van Gurp RJ; Stoop H; van der Kwast TH; Trapman J
J Pathol; 2006 Apr; 208(5):699-707. PubMed ID: 16402365
[TBL] [Abstract][Full Text] [Related]
19. A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays.
Huang W; Hennrick K; Drew S
Hum Pathol; 2013 Jan; 44(1):29-38. PubMed ID: 22944297
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
